14h
MyChesCo on MSNEndo, Inc. Shares Positive Data on XIAFLEX Treatment for Peyronie’s DiseaseEndo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® ...
CMS issued its Final Rule, establishing new Clinical Laboratory Improvement Amendments (CLIA) regulations (the Final ...
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...
Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature ...
Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...
We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...
Natural products industry companies share overviews on the latest science on their branded ingredients and formulations to ...
The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.
Targeted chemotherapy in the abdomen using a technique called PIPAC combined with systemic standard-of-care chemotherapy is shown to be safe, with promising activity for patients with colorectal and a ...
A September 2024 article in the journal Biomedicines reviewing the findings of clinical trials for ivermectin and chloroquine ...
Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...
CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results